Literature DB >> 20448212

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Wolfgang Lieb1, Philimon Gona, Martin G Larson, Joseph M Massaro, Izabella Lipinska, John F Keaney, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S Fox, Ramachandran S Vasan, Emelia J Benjamin, Christopher J O'Donnell, Sekar Kathiresan.   

Abstract

OBJECTIVE: Experimental evidence identified the osteoprotegerin (OPG)/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand (RANKL) pathway as a candidate system modulating vascular remodeling and cardiovascular disease (CVD). METHODS AND
RESULTS: Serum concentrations of OPG and RANKL were measured in 3250 Framingham Study participants (54% women, 61+/-9 years). During a mean follow-up of 4.6 years, 143 (of 3084 free of CVD at baseline) participants developed a first CVD event, and 235 died. In multivariable models, OPG was associated with increased hazards for incident CVD and mortality (hazard ratio, 1.27; 95% CI, 1.04 to 1.54; and hazard ratio, 1.25; 95% CI, 1.07 to 1.47, per 1-SD increment in log-OPG, respectively). Log-OPG was positively related to multiple CVD risk factors, including age, smoking, diabetes, systolic blood pressure, and prevalent CVD. In a subsample (n=1264), the prevalence of coronary artery calcification, measured by computed tomography, increased nonsignificantly with OPG quartiles. RANKL concentrations displayed inverse associations with multiple CVD risk factors, including smoking, diabetes, and antihypertensive treatment, and were not related to coronary artery calcification or incident CVD or mortality.
CONCLUSIONS: Our prospective data reinforce OPG as marker for CVD risk factor burden and predictor for CVD and mortality in the community.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448212      PMCID: PMC3039214          DOI: 10.1161/ATVBAHA.109.199661

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  26 in total

1.  Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men.

Authors:  Michael Schoppet; Juergen R Schaefer; Lorenz C Hofbauer
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

2.  Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

Authors:  P A Price; H H June; J R Buckley; M K Williamson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

Review 3.  The emerging concept of vascular remodeling.

Authors:  G H Gibbons; V J Dzau
Journal:  N Engl J Med       Date:  1994-05-19       Impact factor: 91.245

4.  Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

Authors:  U M Malyankar; M Scatena; K L Suchland; T J Yun; E A Clark; C M Giachelli
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

5.  Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease.

Authors:  Shuichi Jono; Yuji Ikari; Atsushi Shioi; Katsuhito Mori; Takami Miki; Kazuhiro Hara; Yoshiki Nishizawa
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

6.  Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.

Authors:  Stefan Kiechl; Georg Schett; Gregor Wenning; Kurt Redlich; Martin Oberhollenzer; Agnes Mayr; Peter Santer; Josef Smolen; Werner Poewe; Johann Willeit
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

7.  Soluble RANKL and risk of nontraumatic fracture.

Authors:  Georg Schett; Stefan Kiechl; Kurt Redlich; Friedrich Oberhollenzer; Siegfried Weger; Georg Egger; Agnes Mayr; Josef Jocher; Qingbo Xu; Peter Pietschmann; Steven Teitelbaum; Josef Smolen; Johann Willeit
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

8.  Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients.

Authors:  Kosaku Nitta; Takashi Akiba; Keiko Uchida; Shigeru Otsubo; Takashi Takei; Wako Yumura; Takashi Kabaya; Hiroshi Nihei
Journal:  Nephrol Dial Transplant       Date:  2004-05-05       Impact factor: 5.992

9.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

10.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

View more
  50 in total

1.  Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.

Authors:  I G Poornima; K Shields; L H Kuller; S M Manzi; R Ramsey-Goldman; C Richardson; E Rhew; D D Dunlop; J Song; D Edmundowicz; G T Kondos; J J Carr; C B Langman; H Price; A H Chung; L B Santelices; R H Mackey
Journal:  Lupus       Date:  2018-01-01       Impact factor: 2.911

Review 2.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

3.  Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.

Authors:  Jiajia Xia; Linman Li; Wei Ren; Xiaoya Zheng; Chan Liu; Jinchao Li; Tingying Chen; Xiaofeng Li; Lingli Wang; Yumei Hu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.

Authors:  Julia J Scialla; Mary B Leonard; Raymond R Townsend; Lawrence Appel; Myles Wolf; Matt J Budoff; Jing Chen; Eva Lustigova; Crystal A Gadegbeku; Melanie Glenn; Asaf Hanish; Dominic Raj; Sylvia E Rosas; Stephen L Seliger; Matthew R Weir; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

5.  Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.

Authors:  Muyesser Sayki Arslan; Esra Tutal; Mustafa Sahin; Melia Karakose; Bekir Ucan; Gulfer Ozturk; Erman Cakal; Zeynep Biyikli Gencturk; Mustafa Ozbek; Tuncay Delibasi
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

Review 6.  The role of the RANKL/RANK/OPG system in the central nervous systems (CNS).

Authors:  Reiko Hanada
Journal:  J Bone Miner Metab       Date:  2020-09-04       Impact factor: 2.626

7.  Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.

Authors:  Michalis Spartalis; Aikaterini Papagianni
Journal:  World J Nephrol       Date:  2016-01-06

8.  Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.

Authors:  Romina di Giuseppe; Ronald Biemann; Janine Wirth; Juliane Menzel; Berend Isermann; Gabriele I Stangl; Andreas Fritsche; Heiner Boeing; Matthias B Schulze; Cornelia Weikert
Journal:  Eur J Epidemiol       Date:  2016-06-15       Impact factor: 8.082

9.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

10.  Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients.

Authors:  Federico Biscetti; Giuseppe Straface; Silvia Giovannini; Angelo Santoliquido; Flavia Angelini; Luca Santoro; Carlo Filippo Porreca; Giovanni Pecorini; Giovanni Ghirlanda; Andrea Flex
Journal:  Hum Genet       Date:  2012-09-11       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.